CVE:BCT BriaCell Therapeutics (BCT) Stock Price, News & Analysis C$10.60 -0.42 (-3.81%) As of 12/30/2021 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BriaCell Therapeutics Stock (CVE:BCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BriaCell Therapeutics alerts:Sign Up Key Stats Today's RangeC$10.60▼C$11.0750-Day RangeC$10.60▼C$10.6052-Week RangeC$3.50▼C$15.75Volume3,402 shsAverage Volume12,671 shsMarket CapitalizationC$168.68 millionP/E RatioN/ADividend YieldN/APrice TargetC$15.00Consensus RatingN/A Company Overview BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. Read More Receive BCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCT Stock News HeadlinesBriaCell Therapeutics Slide After Equity OfferJuly 15 at 6:37 PM | marketwatch.comBriaCell Therapeutics Announces Pricing of $15 million Public OfferingJuly 15 at 6:37 PM | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 18 at 2:00 AM | Paradigm Press (Ad)BriaCell’s Bria-IMT™ Demonstrates Survival ... - Seeking AlphaJuly 13, 2025 | seekingalpha.comBriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy ...July 13, 2025 | morningstar.comMBriaCell Therapeutics Corp.: BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS Metastatic Breast Cancer StudyJuly 9, 2025 | finanznachrichten.deBriaCell Therapeutics stock tumbles after announcing public offeringJuly 9, 2025 | au.investing.comHere's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn SituationJune 25, 2025 | finance.yahoo.comSee More Headlines BCT Stock Analysis - Frequently Asked Questions How have BCT shares performed this year? BriaCell Therapeutics' stock was trading at C$10.60 at the beginning of 2025. Since then, BCT shares have increased by 0.0% and is now trading at C$10.60. How do I buy shares of BriaCell Therapeutics? Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of BriaCell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), BMO MSCI India ESG Leaders Index ETF (ZID), Athersys (ATHX), Anavex Life Sciences (AVXL), Cardium Therapeutics (CRXM) and Inovio Pharmaceuticals (INO). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:BCT CIKN/A Webwww.briacell.com Phone+1-604-9211810FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for BriaCell TherapeuticsC$15.00 High Price TargetC$15.00 Low Price TargetC$15.00 Potential Upside/Downside+41.5%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio129.63 Quick Ratio128.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$3.34 per share Price / Cash Flow3.17 Book ValueC$3.60 per share Price / Book2.94Miscellaneous Outstanding Shares15,913,000Free FloatN/AMarket CapC$168.68 million OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (CVE:BCT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.